Undoubtedly, these findings could be utilised to target regulatory enhancer axes, and/or key epigenetic enzymes such as DOT1L or LSD1 in LSC from MLLr‐or other leukaemia subtypes (discussed further in therapy section). This evidence concerns the gene DOT1L and leukemia.